Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.43 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4608897 | 1.00 | ANPEP (0.43) | ANPEPERAP1ERAP2TAAR1MEN1 | |
| SCHEMBL3670997 | 0.81 | EPHX1 (0.50) | ANPEPTAAR1CYP2A6EPHX1SLC6A2 | |
| SCHEMBL5732556 | 0.81 | EPHX1 (0.50) | ANPEPTAAR1CYP2A6EPHX1SLC6A2 | |
| SCHEMBL4912039 | 0.81 | EPHX1 (0.50) | ANPEPTAAR1CYP2A6EPHX1SLC6A2 | |
| SCHEMBL1683190 | 0.81 | EPHX1 (0.50) | ANPEPTAAR1CYP2A6EPHX1SLC6A2 | |
| SCHEMBL6562522 | 0.81 | EPHX1 (0.50) | ANPEPTAAR1CYP2A6EPHX1SLC6A2 | |
| SCHEMBL1817802 | 0.81 | EPHX1 (0.50) | ANPEPTAAR1CYP2A6EPHX1SLC6A2 | |
| SCHEMBL3870627 | 0.81 | EPHX1 (0.50) | ANPEPTAAR1CYP2A6EPHX1SLC6A2 | |
| SCHEMBL3134409 | 0.80 | ANPEP (0.42) | ANPEPERAP1ERAP2TAAR1CYP2A6 | |
| SCHEMBL11246640 | 0.78 | KDM4E (0.45) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250108031-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2025-04-03 | — | — | US | disclosed |
| CN-113967258-B | FAP-activated therapeutic agents and related uses | 塔夫茨大学信托人 | 2024-07-02 | — | — | CN | disclosed |
| CN-113967258-A | FAP-activated therapeutics and uses related thereto | 塔夫茨大学信托人 | 2022-01-25 | — | — | CN | disclosed |
| CN-113956325-A | FAP-activated therapeutics and uses related thereto | 塔夫茨大学信托人 | 2022-01-21 | — | — | CN | disclosed |
| CN-113786495-A | FAP-activated therapeutics and uses related thereto | 塔夫茨大学信托人 | 2021-12-14 | — | — | CN | disclosed |
| CN-106573073-B | FAP-activated therapeutics and uses related thereto | 塔夫茨大学信托人 | 2021-09-28 | — | — | CN | disclosed |
| EP-3251674-A2 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | BioCryst Pharmaceuticals, Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-3154594-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | Trustees Of Tufts College (US) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015192124-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2015-12-17 | — | — | WO | disclosed |
| WO-2015192123-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2015-12-17 | — | — | WO | disclosed |
| WO-2011056415-A1 | METHODS FOR QUANTIFYING VITAMIN D METABOLITES BY MASS SPECTROMETRY | GEORGETOWN UNIVERSITY (US) | 2011-05-12 | — | — | WO | disclosed |
| EP-2139337-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN, AND METHODS OF USE THEREOF | Trustees Of Tufts College (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2009149148-A2 | LONG-ACTING GLP-1 DERIVATIVES, AND METHODS OF TREATING CARDIAC DYSFUNCTION | TRUSTEES OF TUFTS COLLEGE (US) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009006473-A2 | PRO-SOFT POLYPEPTIDE PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2008128064-A2 | TRUNCATED ANALOGS OF PEPTIDE AND POLYPEPTIDE THERAPEUTICS | TRUSTEES OF TUFTS COLLEGE (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008119005-A1 | 3,4-DEHYDRO-PROLINE-CONTAINING INHIBITORS OF DIPEPTIDYLPEPTIDASE IV | TRUSTEES OF TUFTS COLLEGE (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008118848-A1 | N-SUBSTITUTED PEPTIDOMIMETIC INHIBITORS OF DIPEPTIDYLPEPTIDASE IV | TRUSTEES OF TUFTS COLLEGE (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116053-A2 | FAP-ACTIVATED CHEMOTHERAPEUTIC COMPOUNDS, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008116054-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008022015-A2 | RETRO-INVERSO INCRETIN ANALOGUES, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250108031-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | ANPEP 93/4885ERAP1 25/4885ERAP2 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.